Purpose To create new immunodeficient Royal College of Surgeons (RCS) rats by introducing the defective MerTK gene into athymic nude rats. Methods Female homozygous RCS (RCS-p+/RCS-p+) and male nude rats (Hsd:RH-Foxn1 mu , mutation in the foxn1 gene; no T cells) were crossed to produce heterozygous F1 progeny. Double homozygous F2 progeny obtained by crossing the F1 heterozygotes was identified phenotypically (hair loss) and genotypically (RCS-p+ gene determined by PCR). Retinal degenerative status was confirmed by optical coherence tomography (OCT) imaging, electroretinography (ERG), optokinetic (OKN) testing, superior colliculus (SC) electrophysiology, and by histology. The effect of xenografts was assessed by transplantation of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) and human-induced pluripotent stem cell-derived RPE (iPS-RPE) into the eye. Morphological analysis was conducted based on hematoxylin and eosin (H&E) and immunostaining. Age-matched pigmented athymic nude rats were used as control. Results Approximately 6% of the F2 pups (11/172) were homozygous for RCS-p+ gene and Foxn1 mu gene. Homozygous males crossed with heterozygous females resulted in 50% homozygous progeny for experimentation. OCT imaging demonstrated significant loss of retinal thickness in homozygous rats. H&E staining showed photoreceptor thickness reduced to 1-3 layers at 12 weeks of age. Progressive loss of visual function was evidenced by OKN testing, ERG, and SC electrophysiology. Transplantation experiments demonstrated survival of human-derived cells and absence of apparent immune rejection. Conclusions This new rat animal model developed by crossing RCS rats and athymic nude rats is suitable for conducting retinal transplantation experiments involving xenografts.
Introduction
Age-related macular degeneration (AMD) and retinitis pigmentosa (RP) lead to a profound loss of vision in millions worldwide. Many of these patients require replacement of both retinal pigment epithelium (RPE) and photoreceptors (PRs). Cell-based techniques for the replacement of RPE, photoreceptors, and other inner retinal cells have been a major focus for various research groups [1] [2] [3] [4] . Promising techniques are now emerging with the potential to replace even retinal ganglion cells and their axons in the optic nerve [5] . Other approaches are aimed at curing retinal degenerative (RD) diseases based on the transplantation of retinal progenitor cells (RPCs). Transplantation studies involving both RPE and retinal progenitor cells have been demonstrated in animal models [4, [6] [7] [8] and humans [9] by grafting sheets of fetal-derived neural retinal progenitor cells with its RPE.
The dystrophic Royal College of Surgeons (RCS) rats [10, 11] and various lines of transgenic S334ter rats [12] [13] [14] are the most commonly used rat disease models in ophthalmic research. These models are commonly used for the assessment of beneficial effects of cell replacement therapies [15] [16] [17] [18] [19] [20] [21] [22] . The dystrophic RCS rats are characterized by RPE dysfunction due to the deletion in the Mer tyrosine kinase (MerTK) receptor that abolishes internalization of PR outer segments by RPE cells [23] . The phagocytosis of shed photoreceptor outer segments (OS) is a prerequisite for maintaining normal retinal physiology for which RPE plays a major role. Accumulation of debris in the subretinal space can lead to severe photoreceptor degeneration and rapid loss of vision. In RCS rats, although retinal thickness remains close to the level of normal eyes at 1 month of age [24, 25] , the outer nuclear layer (ONL) is reduced to a single layer at the age of 3 months, with the debris zone occupying the former outer segment area. Finally, at 6 months, the inner nuclear layer is in direct contact with the RPE cell layer, with very few photoreceptors surviving [26] [27] [28] [29] [30] .
Although the retina is considered an immune privileged area, some immunological reactions to xenograft can occur. Most of the preclinical studies involving human-derived cells used animal models that are exposed to severe immunosuppression regimes [31, 32] . Based on the studies conducted in our laboratory, administration of immunosuppressants in rodents can yield only partial success because of the inconsistent blood immunosuppression levels. The procedure itself is labor intensive and may cause additional pain and discomfort to the animals. Based on a recent investigation, a standard regimen of cyclosporine A plus dexamethasone administered to RCS rats resulted in demonstrable systemic side effects and depressed scores on behavioral and electrophysiological testing [33] . Further, according to Anderson et al. [34] , the presence of an active immunorejection response itself may significantly alter the efficacy and critically, the safety profile of the cell therapy candidate. Recently, Zhu et al. [35] demonstrated that using an immunodeficient model enhances long-term functional integration of human embryonic stem cell (hESC)-derived PRs. The above findings suggest the importance of using immunodeficient models for testing replacement therapies involving human-derived cells. The only immunodeficient RD rat model currently available is S334ter line-3 rats [36] , a model for photoreceptor degeneration showing certain similarities to human retinitis pigments (RP). Contrary to this, the RCS rats are considered as a model suitable for studying RPE dysfunction/disease and early stage interventions based on RPE replacement. Here, we report creating an immunodeficient rat model that manifests the dystrophic features of RCS rats and hence can be considered as desirable for conducting xenograft studies. 
Methods

Animals
Breeding scheme
Adult female RCS rats were mated with athymic nude male rats. Males and females of the F1 progeny from different litters were crossed to produce F2 generation. RCS-p+ gene status of the pups was identified by genotyping. Immunodeficiency status was established based on phenotypic expression (hair loss). Since immunodeficient females are incapable of raising pups, only heterozygous females (phenotypically nonimmunodeficient) were used in all subsequent breeding. These females were crossed with double homozygous (immunodeficient and retinal dystrophic) males to produce approximately 50% double homozygous (dystrophic and immunodeficient) pups. All rats were kept in an aseptic and temperaturecontrolled environment.
Genotyping
The genotyping for RCS/MerTK-alleles was performed with the RRRC (Rat Resource & Research Center) 662 protocol and with the PCR-RFLP assay reported by Hirasawa et al. previously [37] , see Table 1 for details.
Retinal thickness measured using optical coherence tomography imaging
Spectral domain optical coherence tomography (SD-OCT) images of the retina were obtained using a Bioptigen Envisu R2200 spectral domain ophthalmic imaging system (Bioptigen, Research Triangle Park, NC). Rats were anesthetized, and pupils were dilated using 1% atropine drops (Akorn Pharmaceuticals, Lake Forest, IL). During imaging, the animals were placed on a movable platform that allowed easy maneuvering of the head. The eyes were protected by a frequent application of Systane ® (Alcon) to minimize the refractive errors and avoid ocular damage by keeping the cornea moist. From each eye, five scan acquisitions were taken. Areas of 2.6 mm × 2.6 mm were imaged with one of the three following scan parameters (units are # B-scans/# A-scans/Bscan averaging value): 488 × 488 × 5 (optimal for obtaining maximum projection fundus image); 700 × 70 × 25; and 800 × 20 × 80 (optimal for obtaining retinal cross sections).
Optokinetic testing
Optokinetic (OKN) testing was performed at three different time points as previously described [38] . An EthoVision® XT, Noldus Information Technology computer program was used to generate alternate black and white stripes. The headtracking responses during clockwise (1 min) and anticlockwise (1 min) stripe rotations were recorded using a digital camcorder. Visual acuity was tested by the decrease of stripe width at 0.5 decrements. Video recordings were evaluated to compute the head-tracking scores by two separate investigators whom were both blind to the experimental condition.
Electroretinography testing
Electroretinography (ERG) was performed every month after birth using the HMsERG system (Ocuscience, Las Vegas, NV) as previously described [8] . Briefly, after dark adapted overnight, the rats were anesthetized with an injection of ketamine/xylazine (37.5 mg/kg ketamine and 5 mg/kg xylazine, i.p.) and 0-2% isoflurane mixed with oxygen through a gas anesthesia mask (Stoelting, Wood Dale, IL, USA); and eyes were dilated using tropicamide 1% (Bausch & Lomb Inc., Tampa, FL) eye drops. Contact lens electrodes were placed on the cornea of both eyes, with reference and ground electrodes placed subcutaneously. An optically clear ophthalmic gel was used to maintain hydration and conductivity between the cornea and recording electrodes. Scotopic testing was conducted with flash stimuli intensities ranging from 1 to 25,000 millicandela (mcd) followed by photopic testing (light adaptation of 10 min prior to the photopic test which records flash stimuli responses of 10-25,000 mcd).
Superior colliculus electrophysiology
Electrophysiological mapping of the superior colliculus (SC) was performed at about 21 weeks post-surgery. During SC mapping, the responses were recorded from approximately 30 different SC locations. At each location, the recordings were made at varying light intensity (~0.25 steps) to obtain a luminance threshold map of the SC as described previously [7, 39, 40] .
Preparation of iPS-RPE and hESC-RPE cell suspension
The iPS cell line generated from healthy adult fibroblast cells and differentiated into RPE cells (frozen passage 2 cells) was obtained from Dr. Kapil Bharti (National Institute of Health, Bethesda, MD, USA) [41, 42] . Human embryonic stem cells (NIH-registered H9 cell line, WiCell Research Institute, Inc., Madison, WI, USA) were allowed to spontaneously differentiate into RPE cells. Passage 3 iPSC-RPE and hESC-RPE that had been cultured in vitronectin-coated culture dishes for 4 weeks were used for subretinal injections. The cells were dissociated from the culture dishes by TrypLE (Life Technologies) and suspended in DMEM/F12 medium to a final concentration of 5 × 10 7 cells/mL.
Cell suspension injection in RCS rats
Male and female double homozygous (immunodeficient) RCS rats (P28-P30) were used for iPS-RPE (n = 8) and hESC-RPE (n = 5) cell suspension injection experiments. Immunodeficient RCS rats (no surgery, n = 5) and nonimmunodeficient RCS rats (hESC-RPE suspension injection, n = 5) were used as control groups. The rats were anesthetized and placed under a surgical microscope, and their pupils were pharmacologically dilated. A temporal peritomy was made on the left eye, and the superior and lateral recti were isolated. A 4-0 silk suture was passed under these two muscles and used to mechanically hold the eye in the desired position. A 27- gauge needle was used to make a scleral incision of approximately 1.2 mm, approximately 1.5 mm posterior to the limbus at the temporal equator. An anterior chamber paracentesis was performed to lower the intraocular pressure. A 32-gauge needle was then inserted into the subretinal space through the aforementioned scleral incision. Two microliters of cell mixture containing approximately 10 5 cells was injected into the subretinal space. Successful injection created a local retinal detachment (bleb) that was confirmed during fundus examination.
Histological assessments
Anesthetized animals were euthanized with intracardiac injection of 0.5 mL pentobarbital sodium 390 mg and phenytoin sodium 50 mg (Euthasol; Virbac AH, Inc., Fort Worth, TX). Both right and left eyes were enucleated and fixed using Davidson's solution for at least 18 h before embedded in paraffin. Microtome sections (5 μm thickness) passing through the center of optic nerve were stained using hematoxylin and eosin (H&E), and adjacent slides were used for immunostaining. TRA-1-85 (human-specific marker), RPE65 (RPE-specific marker), CD68 (macrophage-specific marker), and GFAP (glial cell-specific marker) primary antibodies were used for immunofluorescence assays. H&E-stained retinal sections were imaged with an Aperio ScanScope, and immunofluorescentstained sections were imaged using a digital microscope BZ-X700 E (Keyence America, IL, USA).
Statistics
Statistical comparisons were made using Graphpad Prism software (Graphpad Software Inc., La Jolla, CA). Paired t test was used for analyzing the OKN data. Rest of the data was analyzed using Student's t test or analysis of variance (ANOVA) followed by appropriate post hoc test. For all comparisons, the significance level was determined at p < 0.05. Age-matched normal pigmented athymic nude rats were used as controls for all experiments.
Results
Breeding of immunodeficient RCS rats
Successful crossbreeding between dystrophic RCS rats and immunodeficient athymic nude rats ( Fig. 1 ) was possible as evidenced by normal litter size (6-13 pups per litter), pup survival, and age of weaning. Immunodeficient pups (phenotypically discernable based on hair loss) were smaller in body size compared to their non-immunodeficient counterparts. Based on genotypic (Fig. 2) and phenotypic characteristics, the double homozygotes were identified from the F2 progeny.
Based on this, 6% of the F2 pups (11/172) homozygous for RCS-p+ gene also showed phenotypic features of nude rats (hairlessness) and hence considered as double homozygous (immunodeficient RCS rats).
Dystrophic characteristics of immunodeficient RCS rats based on histological analysis
In RCS rats, retinal degeneration starts early in life and progresses quickly. In the new double homozygous RCS model (RCS-p+ gene and features of nude rats confirmed), signs of photoreceptor loss were observed at the age of P28 (Fig. 3b) . Only 2-3 layers of outer nuclei were present at the age of 2 months (Fig. 3c) . More or less complete loss of photoreceptors was observed after the age of 4 months (Fig. 3d) .
Progressive loss of retinal thickness in immunodeficient RCS rats demonstrated by OCT imaging
OCT imaging was performed in dystrophic (RCS) immunodeficient rats at various postnatal time points. At the age of 1 month (Fig. 4b) , the retinal thickness was comparable to that of age-matched non-dystrophic immunodeficient rats (nondystrophic athymic nude rat, Fig. 4a ). Considerable loss of retinal thickness was observed in these rats when assessed at the age of 2 months (Fig. 4c) . Progressive loss of retinal thickness was observed in immunodeficient RCS rats tested during the subsequent time points (Fig. 4d-f) . Quantitative measurement of retinal thickness made using cross-sectional OCT images also showed significant loss of retinal thickness in 3-month-old immunodeficient RCS rats compared to nondystrophic immunodeficient (athymic nude) rats (p < 0.001, Fig. 5 ). The above observations are consistent with the pattern of retinal dystrophy observed in non-immunodeficient RCS rats [43, 44] .
Visual functional loss in double homozygous rats demonstrated by optokinetic testing
The visual functional deficit in RCS nude rats was shown by severe loss of OKN visual acuity (Fig. 6) . Although OKN visual activity initially (up to postnatal, P45) remained close to the level of normal rats, significant decrease in visual function was observed after P60. No apparent OKN visual behavioral activity was noticed after the age of 6 months.
Electroretinography testing in immunodeficient RCS rats showed progressive loss of retinal function Electroretinography (ERG) recording was conducted in immunodeficient RCS rats once a month. The immunodeficient ) and female dystrophic RCS rats (RCS-p+ strain, Mat LaVail, UCSF) to generate F1 pups. The F1 rats were crossed to generate F2 litters. Pups that are double homozygous (homozygous for RPE dysfunction disease and immunodeficiency) were identified from the F2 generation based on phenotypic and genotypic characteristics RCS rats showed considerably low scotopic and photopic Aand B-wave amplitudes. The scotopic A-wave and B-wave and photopic B-wave amplitudes were significantly decreased as the rats aged and reached baseline level by 3 to 4 months of age (Fig. 7) . The size of photopic A-wave was too small to demonstrate a clear trend. 
Progressive visual loss in immunodeficient RCS rats demonstrated by superior colliculus electrophysiology
Electrophysiological mapping of the SC visual activity demonstrated progressive loss visual function and development of a scotoma in immunodeficient RCS rats which is typical for its non-immunodeficient counterparts [43] . SC visual activity was considerably attenuated at 8 weeks of age. When tested at P180 (24 weeks of age), the presence of a large scotoma was apparent in the SC with most of the SC surface devoid of any light-evoked activity even at high luminescent levels (Fig. 8) .
Transplantation studies showed survival of human-derived grafts in immunodeficient RCS rats Athymic nude rats generally show only mild immune response to xenografts because of their absence of T cells and lack of natural cell-mediated cytotoxicity. To test whether our new rat model (immunodeficient RCS rats) maintains low immune cellmediated reactions, iPS-RPE and hESC-RPE cells were injected into the subretinal space of double homozygous and founder RCS rats. Histological evaluation of the implanted eyes showed that human-derived iPS-RPE cells well survived in the subretinal space of immunodeficient RCS at 6-month post-injection and were expected to survive longer (Figs. 9 and 10) . At 1 month time point, the injected hESC-RPE cells showed good survival in the eyes of both immunodeficient and nonimmunodeficient strains. In these rats, considerably less expression of CD68, a macrophage marker, and GFAP, a retinal glial marker, was observed (Fig. 10) . The above data suggests lower immune reaction to xenografts in immunodeficient RCS rats. At 6 month post-surgery, no major difference in macrophage (CD68) and retinal glial cells (GFAP) was observed either in the RPE injection area (Fig. 9) or non-injection sites (data not shown), compared to non-injected immunodeficient RCS rats. The expression of immunological markers comparable to the control group suggests absence of apparent chronic inflammation induced by xenografts.
Discussion
In the present study, a new immunodeficient RCS rat model was created. Manifestation of RCS characteristics in this new rat model is demonstrated based on PCR analysis, visual functional assessments, and histological evaluation. This study also demonstrated success of xenograft experiments in this new rat model without administering immunosuppressant drugs. Immunodeficient RD models are valuable for xenograft experiments since most of the preclinical investigational new drug (IND) studies based on cell replacement therapies require experiments conducted using both immunodeficient models and disease models. In the absence of such double homozygous models, non-immunodeficient animals are subjected to severe immunosuppression regimes to avoid graft rejection. For example, our preclinical studies of hESC-RPE implantation-utilized dystrophic RCS rats subjected to systemic administration of dexamethasone and cyclosporine [45] . Other investigators also employed a similar approach in several previous studies [46] [47] [48] [49] [50] [51] [52] [53] [54] .
The athymic nude rat (Foxn1rnu/rnu) is a popular model to test xenografts derived from human tissue [47, [55] [56] [57] [58] . However, since it has a normal retina, it is difficult to evaluate the visual functional benefits of the transplants. The RCS rat which is an RPE dysfunction model has been widely used for assessing cell-based therapies, especially in RPE replacement studies [15, 19, 59] . In these studies, the animals were immunosuppressed using drugs to minimize the tissue rejection and Fig. 6 OKN testing to assess visual functional changes in immunodeficient RCS rats. Visual behavioral assessment based on optokinetic (OKN) testing was performed in dystrophic immunodeficient RCS rats and age-matched non-dystrophic immunodeficient rats at various postnatal (P) time points. After the age of P60, visual acuity decreased considerably in immunodeficient RCS rats, whereas no differences were observed in the control group Fig. 5 Retinal thickness measurements using OCT vertical scan images. Significant loss of retinal thickness (p < 0.001, Student t test, mean ± SEM, n = 6) was observed in immunodeficient RCS rats compared to agematched non-dystrophic athymic nude rats assessed at the age of 3 months to enable faithful assessment of the transplant effects [15, 32, 60, 61] . Based on the studies conducted in our laboratory, administration of immunosuppressants is labor intensive and may cause additional pain and discomfort to the animals. Administration of immunosuppressant may negatively influence the health of the recipient, especially with long-term use [62, 63] . In a recent investigation, standard regimen of cyclosporine A plus dexamethasone was administered to RCS rats that caused systemic side effects and depressed scores on behavioral and electrophysiological testing [33] .
In the present investigation, we were able to confirm the dystrophic features of the new rat model based on genotyping of the MerTK gene. Expression of disease condition was confirmed by histological and visual functional tests. To produce immunodeficient RCS pups, double homozygous males were used for breeding, but the females used were heterozygous for immunodeficiency and homozygous for the RCS mutation. Females heterozygous for immunodeficiency was chosen since their homozygous counterparts are known to be incapable of raising pups. As expected, approximately 50% of the progeny were double homozygous (immunodeficient RCS), whereas the other 50% of the pups were non-immunodeficient (heterozygous for immunodeficiency) but homozygous for RCS mutation. Since the immunodeficient status of the animals was easily discernible based on phenotypic expression (hair loss), no separate genotypic tests were conducted for assessing their immunodeficiency status.
The dystrophic status of the double homozygous (immunodeficient and dystrophic) rats was established based on multiple test modalities. Histological assessments showed that the progression of the RD condition in this new model is comparable to their non-immunodeficient counterparts. The above disease features further confirmed by OCT imaging are in agreement with previous investigations conducted in nonimmunodeficient dystrophic RCS rats [26] [27] [28] [29] [30] . For visual functional assessment, we used behavioral and electrophysiological means. The OKN visual assessment demonstrated visual functional loss in the double homozygous individuals as observed in non-immunodeficient dystrophic RCS rats [45] . Consistent with the histology data, ERG testing (scotopic and photopic) also demonstrated progressive attenuation of retinal visual activity that became almost undetectable by the age of 4 months. The above pattern of visual function loss is comparable to the previous observations in non-immunodeficient RCS rats [64] [65] [66] . Electrophysiological mapping of the SC also revealed loss of visual function as reported in earlier investigations using non-immunodeficient RCS rats [43, 44, 67] .
Most of the investigations involving stem cell-derived therapeutics require testing of the final product in immunodeficient animals to rule out the possibility of tumorigenicity. In our previous investigation, hESC-RPE implants were tested for tumorigenicity using athymic nude rats. This study established absence of tumor formation and immune rejection by hESC-RPE implants [16] . Our new animal model was also tested for immunological reactions by transplanting human-derived cells (iPS-RPE and hESC-RPE). Our studies demonstrated high survival of xenografts in this new RD model in the absence of external immunosuppressant agents. The surviving cells expressed RPE markers and human markers as reported in our previous investigations where systemic administration of immunosuppressant was employed [45] . Further, less immunological reaction (based on CD 68 and GFAP expression) was observed in immunodeficient strains compared to their non-immunodeficient counterparts. It is possible that survival of the transplant may not always be indicative of visual functional improvements as evidenced by CNT treatment studies where photoreceptor preservation was observed but visual function was not improved accordingly [68] . The focus of our next study will be to assess how the functionality of the transplanted human-derived RPE cells is affected in this new animal model.
In conclusion, our new rat model showing dystrophic features of RCS rats and immunodeficiency status of athymic nude rats is useful for studying the survival and functionality of human-derived cells. Importantly, this new model provides a desirable RD rat model to conduct cell transplantation experiments without involving the adverse effects of immunosuppression. By using this model, it is possible to reduce the total animal number and number of study groups leading to faster completion of research projects. Based on this, INDenabling preclinical studies can be much faster and cost-effective, and ethical concerns related to the use of laboratory animals can be considerably reduced. 
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